Last $0.80 USD
Change Today 0.00 / 0.00%
Volume 0.0
TELK On Other Exchanges
Symbol
Exchange
OTC US
Munich
As of 8:10 PM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

telik inc (TELK) Snapshot

Open
$0.80
Previous Close
$0.80
Day High
$0.80
Day Low
$0.80
52 Week High
11/7/13 - $2.15
52 Week Low
08/8/14 - $0.68
Market Cap
11.1M
Average Volume 10 Days
15.7K
EPS TTM
$-1.00
Shares Outstanding
13.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TELIK INC (TELK)

Related News

No related news articles were found.

telik inc (TELK) Related Businessweek News

No Related Businessweek News Found

telik inc (TELK) Details

Telik Inc., a clinical stage drug development company, engages in discovering, developing, and commercializing small molecule drugs to treat cancer and other diseases. It offers TELINTRA, a small molecule bone marrow stimulant for myelodysplastic syndrome and severe chronic idiopathic neutropenia, as well as for the treatment of additional blood disorders, such as multiple myeloma or chemotherapy induced neutropenia. The company also offers TELCYTA, a cancer cell-activated chemotherapeutic molecule that is in development for ovarian and non-small cell lung cancer. Telik Inc. was incorporated in 2006 and is based in San Diego, California.

10 Employees
Last Reported Date: 05/23/14
Founded in 2006

telik inc (TELK) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

telik inc (TELK) Key Developments

Telik Inc. Announces Board Appointments

Telik Inc. announced the appointment of six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger. J. David Hansen has served as MabVax's President, Chief Executive Officer, and Member of its Board of Directors since co-founding MabVax in 2006. Mr. Hansen is an experienced biopharmaceutical executive with more than 30 years of industry experience. From 1998 to 2006, Mr. Hansen was a corporate officer of Avanir Pharmaceuticals, where he held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences. Prior to 1999 Mr. Hansen served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development, and at Merck & Co. (Schering-Plough), Key Pharmaceuticals, and Bristol Myers Squibb. Philip O. Livingston, M.D. is a co-founder and has been a member of MabVax's Board of Directors since 2008. Dr. Livingston has served as MabVax's Chief Science Officer since 2012. He received his MD degree from Harvard Medical School and was Professor of Medicine in the Joan and Sanford Weill Medical College at Cornell University and Attending Physician and Member of Memorial Sloan-Kettering Cancer Center, or MSKCC, where he treated melanoma patients and ran the Cancer Vaccinology Laboratory research lab for over 30 years until his retirement from MSKCC in 2011. Jeffrey V. Ravetch, M.D., Ph.D. has been a member of the MabVax Board of Directors since early 2014. Dr. Ravetch has served as the Theresa and Eugene Lang Professor at the Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology since 1997. Kenneth M. Cohen has been a member of the MabVax Board of Directors since mid-2014. Mr. Cohen has been a member of the Board of Directors of Adamis Pharmaceuticals Corporation from 2011 to present. Paul V. Maier has been a member of the MabVax Board of Directors since mid-2014. Mr. Maier has been a member of the Board of Directors of Apricus Biosciences Inc. from 2012 to present. Jim J. Antonopoulos is a Principal in Canaccord Genuity's Investment Banking Group. Mr. Antonopoulos works primarily in the Life Sciences sector, representing pharmaceutical and biotechnology companies. Over the past six years, he has focused on sourcing and supporting the execution of public and private financing engagements as well as advising companies with respect to mergers and acquisitions. Michael M. Wick, M.D., Ph.D. has served as the Company's Chairman of the Board of Directors from 2000 to July 2014. Dr. Wick served as the Company's Chief Executive Officer from 1999 to July 2014 and as its President from 1998 to July 2014. Dr. Wick served as the Company's Chief Operating Officer from 1997 until 1998, and as Executive Vice President, Research and Development, from 1997 until 1998.

Telik Inc. to Approve Amendments to Certificate of Incorporation

Telik Inc. announced that its shareholders at the special meeting to be held on August 20, 2014 will consider and approve an amendment to company's certificate of incorporation to effect a five for one reverse stock split of company’s common stock and related matters and an amendment and restatement of company's certificate of incorporation to increase the number of shares of common stock to a new total of 150,000,000 shares, increase the number of shares of company's preferred stock to a new total of 15,000,000 shares, and change the name of Telik to MabVax Therapeutics Holdings Inc.

Telik Inc., Special/Extraordinary Shareholders Meeting, Aug 20, 2014

Telik Inc., Special/Extraordinary Shareholders Meeting, Aug 20, 2014., at 10:00 Pacific Standard Time. Location: 11588 Sorrento Valley road. Agenda: To approve an amendment to company's certificate of incorporation to effect a five for one reverse stock split of company’s common stock and related matters; to approve an amendment and restatement of company's certificate of incorporation to increase the number of shares of common stock to a new total of 150,000,000 shares, increase the number of shares of company's preferred stock to a new total of 15,000,000 shares, and change the name of Telik to MabVax Therapeutics Holdings, Inc.; to authorize an adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of proposals; and to transact such other business as may be properly brought before the Special Meeting and any adjournments thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TELK:US $0.80 USD 0.00

TELK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TELK.
View Industry Companies
 

Industry Analysis

TELK

Industry Average

Valuation TELK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales NM Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 75.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELIK INC, please visit www.telik.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.